These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 36810856)

  • 61. Transformation to small cell lung cancer as an acquired resistance mechanism in EGFR-mutant lung adenocarcinoma: a case report of complete response to etoposide and cisplatin.
    Hwang KE; Jung JW; Oh SJ; Park MJ; Shon YJ; Choi KH; Jeong ET; Kim HR
    Tumori; 2015 Jun; 101(3):e96-8. PubMed ID: 25908039
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
    VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
    Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology.
    Norkowski E; Ghigna MR; Lacroix L; Le Chevalier T; Fadel É; Dartevelle P; Dorfmuller P; Thomas de Montpréville V
    J Thorac Oncol; 2013 Oct; 8(10):1265-71. PubMed ID: 24457237
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901).
    Li XM; Li WF; Lin JT; Yan HH; Tu HY; Chen HJ; Wang BC; Wang Z; Zhou Q; Zhang XC; Su J; Chen RL; Wu YL; Yang JJ
    Clin Lung Cancer; 2021 Mar; 22(2):100-109.e3. PubMed ID: 33317922
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.
    Vokes NI; Chambers E; Nguyen T; Coolidge A; Lydon CA; Le X; Sholl L; Heymach JV; Nishino M; Van Allen EM; Jänne PA
    J Thorac Oncol; 2022 Jun; 17(6):779-792. PubMed ID: 35331964
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Small cell lung cancer transformation: From pathogenesis to treatment.
    Yin X; Li Y; Wang H; Jia T; Wang E; Luo Y; Wei Y; Qin Z; Ma X
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):595-606. PubMed ID: 35276343
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Intrapatient Molecular and Histologic Heterogeneity After First-generation or Second-generation TKI Therapy of NSCLC Patients: Potential Clinical Impact on Subsequent third-generation TKI Treatment.
    Iacono D; Osman GA; Migliorino MR; Grillo L; Remotti D; Nunnari J; Ricciardi S; Rossi A; Mancuso A; Graziano P; Di Lorenzo A; Bronzini M; Signora M; Leone A
    Am J Clin Oncol; 2019 Nov; 42(11):845-850. PubMed ID: 31644442
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.
    Kita K; Fukuda K; Takahashi H; Tanimoto A; Nishiyama A; Arai S; Takeuchi S; Yamashita K; Ohtsubo K; Otani S; Yanagimura N; Suzuki C; Ikeda H; Tamura M; Matsumoto I; Yano S
    Cancer Sci; 2019 Oct; 110(10):3215-3224. PubMed ID: 31432603
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Histologic transformation to small-cell lung cancer following gefitinib and radiotherapy in a patient with pulmonary adenocarcinoma.
    Fiore M; Trecca P; Perrone G; Amato M; Righi D; Trodella L; D'Angelillo RM; Ramella S
    Tumori; 2019 Dec; 105(6):NP12-NP16. PubMed ID: 30799776
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing.
    Sun JM; Choi YL; Ji JH; Ahn JS; Kim KM; Han J; Ahn MJ; Park K
    Ann Oncol; 2015 Jan; 26(1):161-166. PubMed ID: 25355724
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.
    Minari R; Bordi P; Del Re M; Facchinetti F; Mazzoni F; Barbieri F; Camerini A; Comin CE; Gnetti L; Azzoni C; Nizzoli R; Bortesi B; Rofi E; Petreni P; Campanini N; Rossi G; Danesi R; Tiseo M
    Lung Cancer; 2018 Jan; 115():21-27. PubMed ID: 29290257
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report.
    Tomic K; Krpina K; Baticic L; Samarzija M; Vranic S
    J Drug Target; 2024 Jun; 32(5):499-509. PubMed ID: 38506620
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sequential occurrence of small cell and non-small lung cancer in a male patient: Is it a transformation?
    Wahab A; Kesari K; Chaudhary S; Khan M; Khan H; Smith S; Boumber Y
    Cancer Biol Ther; 2017 Dec; 18(12):940-943. PubMed ID: 29157085
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Current knowledge of small cell lung cancer transformation from non-small cell lung cancer.
    Giaccone G; He Y
    Semin Cancer Biol; 2023 Sep; 94():1-10. PubMed ID: 37244438
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
    Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
    Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cells Lacking the
    Oser MG; Fonseca R; Chakraborty AA; Brough R; Spektor A; Jennings RB; Flaifel A; Novak JS; Gulati A; Buss E; Younger ST; McBrayer SK; Cowley GS; Bonal DM; Nguyen QD; Brulle-Soumare L; Taylor P; Cairo S; Ryan CJ; Pease EJ; Maratea K; Travers J; Root DE; Signoretti S; Pellman D; Ashton S; Lord CJ; Barry ST; Kaelin WG
    Cancer Discov; 2019 Feb; 9(2):230-247. PubMed ID: 30373918
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
    Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
    BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.